Roche’s Immuno-Oncology Arsenal: PD-L1 And Beyond
This article was originally published in PharmAsia News
Executive Summary
Roche 
may be playing catch-up to Bristol-Myers Squibb and Merck & Co in the PD-1/PD-L1 checkpoint development space, but it believes its unique in-house strengths in diagnostics and molecular biology, coupled with partnering, will enable it to play a major role in immuno-oncology.
You may also be interested in...
Roche's Oncology Strategy: The Long Game Comes Into Focus
Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.
Beyond PD-1: Roche Maps Further Checkpoints On Cancer Immune Cycle
Roche gave updates on its immunotherapy research at ASCO, setting the stage for an ambitious slate of combination trials with the company's PD-L1 inhibitor atezolizumab.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.